Cargando…
Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report
BACKGORUND: Mixed hyperlipidemia is common in patients with diabetes. Statins, the choice drugs, are effective at reducing lipoproteins that contain apolipoprotein B100, but they fail to exert good control over intestinal lipoproteins, which have an atherogenic potential. We describe the effect of p...
Autores principales: | Valdivielso, Pedro, Rioja, José, García-Arias, Carlota, Sánchez-Chaparro, Miguel Angel, González-Santos, Pedro |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2631503/ https://www.ncbi.nlm.nih.gov/pubmed/19133114 http://dx.doi.org/10.1186/1475-2840-8-1 |
Ejemplares similares
-
Lipoprotein lipase activity and mass, apolipoprotein C-II mass and polymorphisms of apolipoproteins E and A5 in subjects with prior acute hypertriglyceridaemic pancreatitis
por: Coca-Prieto, Inmaculada, et al.
Publicado: (2009) -
Postprandial Apolipoprotein B48 is Associated with Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis
por: Mena-Vázquez, Natalia, et al.
Publicado: (2020) -
Postprandial Hyperlipidemia: Association with Inflammation and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis
por: Mena-Vázquez, Natalia, et al.
Publicado: (2022) -
Enantiospecific Pharmacogenomics of Fluvastatin
por: Hirvensalo, Päivi, et al.
Publicado: (2019) -
Omega-3 Fatty Acid Based Nanolipid Formulation of Atorvastatin for Treating Hyperlipidemia
por: Sreedhar, Revathy, et al.
Publicado: (2019)